INVITED REVIEW
Targeting ferroptosis in gastric cancer: Strategies and opportunities
Jiahan Le,
Guangzhao Pan,
Che Zhang,
Yitao Chen,
Amit K. Tiwari,
Jiang-Jiang Qin,
Jiahan Le
School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, China
Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
Search for more papers by this authorGuangzhao Pan
Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
Search for more papers by this authorChe Zhang
Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
School of Molecular Medicine, Hangzhou Institute for Advanced Study, UCAS, Hangzhou, China
Search for more papers by this authorCorresponding Author
Yitao Chen
School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, China
Correspondence
Jiang-Jiang Qin, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
Email: [email protected]
Yitao Chen, School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Email: [email protected]
Amit K. Tiwari, Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Email: [email protected]
Search for more papers by this authorCorresponding Author
Amit K. Tiwari
Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Correspondence
Jiang-Jiang Qin, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
Email: [email protected]
Yitao Chen, School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Email: [email protected]
Amit K. Tiwari, Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Email: [email protected]
Search for more papers by this authorCorresponding Author
Jiang-Jiang Qin
Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
School of Molecular Medicine, Hangzhou Institute for Advanced Study, UCAS, Hangzhou, China
Correspondence
Jiang-Jiang Qin, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
Email: [email protected]
Yitao Chen, School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Email: [email protected]
Amit K. Tiwari, Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Email: [email protected]
Search for more papers by this authorJiahan Le,
Guangzhao Pan,
Che Zhang,
Yitao Chen,
Amit K. Tiwari,
Jiang-Jiang Qin,
Jiahan Le
School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, China
Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
Search for more papers by this authorGuangzhao Pan
Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
Search for more papers by this authorChe Zhang
Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
School of Molecular Medicine, Hangzhou Institute for Advanced Study, UCAS, Hangzhou, China
Search for more papers by this authorCorresponding Author
Yitao Chen
School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, China
Correspondence
Jiang-Jiang Qin, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
Email: [email protected]
Yitao Chen, School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Email: [email protected]
Amit K. Tiwari, Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Email: [email protected]
Search for more papers by this authorCorresponding Author
Amit K. Tiwari
Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Correspondence
Jiang-Jiang Qin, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
Email: [email protected]
Yitao Chen, School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Email: [email protected]
Amit K. Tiwari, Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Email: [email protected]
Search for more papers by this authorCorresponding Author
Jiang-Jiang Qin
Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
School of Molecular Medicine, Hangzhou Institute for Advanced Study, UCAS, Hangzhou, China
Correspondence
Jiang-Jiang Qin, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
Email: [email protected]
Yitao Chen, School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Email: [email protected]
Amit K. Tiwari, Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Email: [email protected]
Search for more papers by this authorThis article is part of a series of reviews covering Mechanisms of programmed cell death appearing in Volume 321 of Immunological Reviews.
Summary
Ferroptosis is a novel form of programmed cell death morphologically, genetically, and biochemically distinct from other cell death pathways and characterized by the accumulation of iron-dependent lipid peroxides and oxidative damage. It is now understood that ferroptosis plays an essential role in various biological processes, especially in the metabolism of iron, lipids, and amino acids. Gastric cancer (GC) is a prevalent malignant tumor worldwide with low early diagnosis rates and high metastasis rates, accounting for its relatively poor prognosis. Although chemotherapy is commonly used to treat GC, drug resistance often leads to poor therapeutic outcomes. In the last several years, extensive research on ferroptosis has highlighted its significant potential in GC therapy, providing a promising strategy to address drug resistance associated with standard cancer therapies. In this review, we offer an extensive summary of the key regulatory factors related to the mechanisms underlying ferroptosis. Various inducers and inhibitors specifically targeting ferroptosis are uncovered. Additionally, we explore the prospective applications and outcomes of these agents in the field of GC therapy, emphasizing their capacity to improve the outcomes of this patient population.
CONFLICT OF INTEREST STATEMENT
The authors have no conflict of interest to declare.
Open Research
DATA AVAILABILITY STATEMENT
Data sharing not applicable—no new data generated.
REFERENCES
- 1Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012; 149: 1060-1072.
- 2Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017; 171: 273-285.
- 3Lewerenz J, Ates G, Methner A, Conrad M, Maher P. Oxytosis/ferroptosis-(re-) emerging roles for oxidative stress-dependent non-apoptotic cell death in diseases of the central nervous system. Front Neurosci. 2018; 12: 214.
- 4Dröge W. Free radicals in the physiological control of cell function. Physiol Rev. 2002; 82: 47-95.
- 5Zhang C, Liu X, Jin S, Chen Y, Guo R. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer. 2022; 21: 47.
- 6Ouyang S, Li H, Lou L, et al. Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer. Redox Biol. 2022; 52:102317.
- 7Nie Z, Chen M, Gao Y, et al. Ferroptosis and tumor drug resistance: current status and major challenges. Front Pharmacol. 2022; 13:879317.
- 8Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting ferroptosis to iron out cancer. Cancer Cell. 2019; 35: 830-849.
- 9Adhikari S, Bhattacharya A, Adhikary S, et al. The paradigm of drug resistance in cancer: an epigenetic perspective. Biosci Rep. 2022; 42: BSR20211812.
- 10Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71: 209-249.
- 11Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017; 153: 420-429.
- 12Smyth EC, Nilsson M, Grabsch HI, van Grieken NCT, Lordick F. Gastric cancer. Lancet. 2020; 396: 635-648.
- 13Guan X, Yang J, Wang W, et al. Dual inhibition of MYC and SLC39A10 by a novel natural product STAT3 inhibitor derived from Chaetomium globosum suppresses tumor growth and metastasis in gastric cancer. Pharmacol Res. 2023; 189:106703.
- 14Bousso P. Diving into the mechanism of action of tumor immunotherapies with intravital imaging. Immunol Rev. 2022; 306: 218-223.
- 15Li K, Zhang A, Li X, Zhang H, Zhao L. Advances in clinical immunotherapy for gastric cancer. Biochim Biophys Acta Rev Cancer. 2021; 1876:188615.
- 16Zhou X, Renauer PA, Zhou L, Fang SY, Chen S. Applications of CRISPR technology in cellular immunotherapy. Immunol Rev. 2023.
- 17Xu Q, Pan G, Wang Z, et al. Platycodin-D exerts its anti-cancer effect by promoting c-Myc protein ubiquitination and degradation in gastric cancer. Front Pharmacol. 2023; 14:1138658.
- 18Liu YP, Qiu ZZ, Li XH, Li EY. Propofol induces ferroptosis and inhibits malignant phenotypes of gastric cancer cells by regulating miR-125b-5p/STAT3 axis. World J Gastrointest Oncol. 2021; 13: 2114-2128.
- 19Chen X, Yu C, Kang R, Tang D. Iron metabolism in ferroptosis. Front Cell Dev Biol. 2020; 8:590226.
- 20Luo L, Wang H, Tian W, Zeng J, Huang Y, Luo H. Targeting ferroptosis for cancer therapy: iron metabolism and anticancer immunity. Am J Cancer Res. 2021; 11: 5508-5525.
- 21Lee JY, Kim WK, Bae KH, et al. Lipid metabolism and ferroptosis. Biology. 2021; 10: 184.
- 22Miess H, Dankworth B, Gouw AM, et al. The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma. Oncogene. 2018; 37: 5435-5450.
- 23Gulec S, Anderson GJ, Collins JF. Mechanistic and regulatory aspects of intestinal iron absorption. Am J Physiol Gastrointest Liver Physiol. 2014; 307: G397-G409.
- 24Brzóska K, Meczyńska S, Kruszewski M. Iron-sulfur cluster proteins: electron transfer and beyond. Acta Biochim Pol. 2006; 53: 685-691.
- 25Fang X, Ardehali H, Min J, Wang F. The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease. Nat Rev Cardiol. 2023; 20: 7-23.
- 26Netz DJ, Stith CM, Stümpfig M, et al. Eukaryotic DNA polymerases require an iron-sulfur cluster for the formation of active complexes. Nat Chem Biol. 2011; 8: 125-132.
- 27Qu L, He X, Tang Q, Fan X, Liu J, Lin A. Iron metabolism, ferroptosis, and lncRNA in cancer: knowns and unknowns. J Zhejiang Univ Sci B. 2022; 23: 844-862.
- 28Andrews NC, Schmidt PJ. Iron homeostasis. Annu Rev Physiol. 2007; 69: 69-85.
- 29Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 2021; 31: 107-125.
- 30Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of mammalian iron metabolism. Cell. 2010; 142: 24-38.
- 31Gao M, Monian P, Quadri N, Ramasamy R, Jiang X. Glutaminolysis and transferrin regulate ferroptosis. Mol Cell. 2015; 59: 298-308.
- 32Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer. 2013; 13: 342-355.
- 33Ohgami RS, Campagna DR, Greer EL, et al. Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat Genet. 2005; 37: 1264-1269.
- 34Hou W, Xie Y, Song X, et al. Autophagy promotes ferroptosis by degradation of ferritin. Autophagy. 2016; 12: 1425-1428.
- 35Stockwell BR. Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications. Cell. 2022; 185: 2401-2421.
- 36Braughler JM, Duncan LA, Chase RL. The involvement of iron in lipid peroxidation. Importance of ferric to ferrous ratios in initiation. J Biol Chem. 1986; 261: 10282-10289.
- 37Liu J, Kang R, Tang D. Signaling pathways and defense mechanisms of ferroptosis. FEBS J. 2022; 289: 7038-7050.
- 38Song Y, Wang B, Zhu X, et al. Human umbilical cord blood-derived MSCs exosome attenuate myocardial injury by inhibiting ferroptosis in acute myocardial infarction mice. Cell Biol Toxicol. 2021; 37: 51-64.
- 39Turcu AL, Versini A, Khene N, et al. DMT1 inhibitors kill cancer stem cells by blocking lysosomal iron translocation. Chemistry. 2020; 26: 7369-7373.
- 40Yu Y, Jiang L, Wang H, et al. Hepatic transferrin plays a role in systemic iron homeostasis and liver ferroptosis. Blood. 2020; 136: 726-739.
- 41Hong X, Roh W, Sullivan RJ, et al. The lipogenic regulator SREBP2 induces transferrin in circulating melanoma cells and suppresses ferroptosis. Cancer Discov. 2021; 11: 678-695.
- 42Wen J, Zheng W, Zeng L, et al. LTF induces radioresistance by promoting autophagy and forms an AMPK/SP2/NEAT1/miR-214-5p feedback loop in lung squamous cell carcinoma. Int J Biol Sci. 2023; 19: 1509-1527.
- 43Deng M, Zhang W, Tang H, et al. Lactotransferrin acts as a tumor suppressor in nasopharyngeal carcinoma by repressing AKT through multiple mechanisms. Oncogene. 2013; 32: 4273-4283.
- 44Wang Y, Liu Y, Liu J, Kang R, Tang D. NEDD4L-mediated LTF protein degradation limits ferroptosis. Biochem Biophys Res Commun. 2020; 531: 581-587.
- 45Lu Y, Yang Q, Su Y, et al. MYCN mediates TFRC-dependent ferroptosis and reveals vulnerabilities in neuroblastoma. Cell Death Dis. 2021; 12: 511.
- 46Song J, Liu T, Yin Y, et al. The deubiquitinase OTUD1 enhances iron transport and potentiates host antitumor immunity. EMBO Rep. 2021; 22:e51162.
- 47Ganz T. Cellular iron: ferroportin is the only way out. Cell Metab. 2005; 1: 155-157.
- 48Geng N, Shi BJ, Li SL, et al. Knockdown of ferroportin accelerates erastin-induced ferroptosis in neuroblastoma cells. Eur Rev Med Pharmacol Sci. 2018; 22: 3826-3836.
- 49Ma S, Henson ES, Chen Y, Gibson SB. Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. Cell Death Dis. 2016; 7:e2307.
- 50Kagan VE, Mao G, Qu F, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017; 13: 81-90.
- 51Dixon SJ, Winter GE, Musavi LS, et al. Human haploid cell genetics reveals roles for lipid metabolism genes in nonapoptotic cell death. ACS Chem Biol. 2015; 10: 1604-1609.
- 52Doll S, Proneth B, Tyurina YY, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017; 13: 91-98.
- 53Yuan H, Li X, Zhang X, Kang R, Tang D. Identification of ACSL4 as a biomarker and contributor of ferroptosis. Biochem Biophys Res Commun. 2016; 478: 1338-1343.
- 54Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol. 2021; 18: 280-296.
- 55Yang WS, Kim KJ, Gaschler MM, Patel M, Shchepinov MS, Stockwell BR. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci U S A. 2016; 113: E4966-E4975.
- 56Yan B, Ai Y, Sun Q, et al. Membrane damage during ferroptosis is caused by oxidation of phospholipids catalyzed by the oxidoreductases POR and CYB5R1. Mol Cell. 2021; 81: 355-369.e310.
- 57Kim JH, Lewin TM, Coleman RA. Expression and characterization of recombinant rat acyl-CoA synthetases 1, 4, and 5. Selective inhibition by triacsin C and thiazolidinediones. J Biol Chem. 2001; 276: 24667-24673.
- 58Magtanong L, Ko PJ, To M, et al. Exogenous monounsaturated fatty acids promote a ferroptosis-resistant cell state. Cell Chem Biol. 2019; 26: 420-432.e429.
- 59Paton CM, Ntambi JM. Biochemical and physiological function of stearoyl-CoA desaturase. Am J Physiol Endocrinol Metab. 2009; 297: E28-E37.
- 60Yang Y, Zhu T, Wang X, et al. ACSL3 and ACSL4, distinct roles in ferroptosis and cancers. Cancers. 2022; 14: 5896.
- 61Zhou H, Li F, Niu JY, et al. Ferroptosis was involved in the oleic acid-induced acute lung injury in mice. Sheng Li Xue Bao. 2019; 71: 689-697.
- 62Kuhn H, Banthiya S, van Leyen K. Mammalian lipoxygenases and their biological relevance. Biochim Biophys Acta. 2015; 1851: 308-330.
- 63Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021; 22: 266-282.
- 64Lin Z, Liu J, Kang R, Yang M, Tang D. Lipid metabolism in ferroptosis. Adv Biol. 2021; 5:e2100396.
- 65Li Y, Maher P, Schubert D. A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion. Neuron. 1997; 19: 453-463.
- 66Wenzel SE, Tyurina YY, Zhao J, et al. PEBP1 wardens ferroptosis by enabling lipoxygenase generation of lipid death signals. Cell. 2017; 171: 628-641.e626.
- 67Liang D, Minikes AM, Jiang X. Ferroptosis at the intersection of lipid metabolism and cellular signaling. Mol Cell. 2022; 82: 2215-2227.
- 68Shah R, Shchepinov MS, Pratt DA. Resolving the role of lipoxygenases in the initiation and execution of ferroptosis. ACS Cent Sci. 2018; 4: 387-396.
- 69Yang J, Dai X, Xu H, Tang Q, Bi F. Regulation of ferroptosis by amino acid metabolism in cancer. Int J Biol Sci. 2022; 18: 1695-1705.
- 70Li Z, Zhang H. Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression. Cell Mol Life Sci. 2016; 73: 377-392.
- 71Angeli JPF, Shah R, Pratt DA, Conrad M. Ferroptosis inhibition: mechanisms and opportunities. Trends Pharmacol Sci. 2017; 38: 489-498.
- 72Shi Z, Naowarojna N, Pan Z, Zou Y. Multifaceted mechanisms mediating cystine starvation-induced ferroptosis. Nat Commun. 2021; 12: 4792.
- 73Tang X, Chen W, Liu H, et al. Research progress on SLC7A11 in the regulation of cystine/cysteine metabolism in tumors. Oncol Lett. 2022; 23: 47.
- 74Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2021; 12: 599-620.
- 75Conrad M, Sato H. The oxidative stress-inducible cystine/glutamate antiporter, system xc−: cystine supplier and beyond. Amino Acids. 2012; 42: 231-246.
- 76Stipanuk MH, Dominy JE Jr, Lee JI, Coloso RM. Mammalian cysteine metabolism: new insights into regulation of cysteine metabolism. J Nutr. 2006; 136: 1652s-1659s.
- 77Sahota A, Tischfield JA, Goldfarb DS, Ward MD, Hu L. Cystinuria: genetic aspects, mouse models, and a new approach to therapy. Urolithiasis. 2019; 47: 57-66.
- 78Kumar A, Ratan RR. Oxidative stress and Huntington's disease: the good, the bad, and the ugly. J Huntingtons Dis. 2016; 5: 217-237.
- 79Gu L, Robinson RA. A simple isotopic labeling method to study cysteine oxidation in Alzheimer's disease: oxidized cysteine-selective dimethylation (OxcysDML). Anal Bioanal Chem. 2016; 408: 2993-3004.
- 80Combs JA, DeNicola GM. The non-essential amino acid cysteine becomes essential for tumor proliferation and survival. Cancers. 2019; 11: 678.
- 81Chio IIC, Tuveson DA. ROS in cancer: the burning question. Trends Mol Med. 2017; 23: 411-429.
- 82Cormerais Y, Giuliano S, LeFloch R, et al. Genetic disruption of the multifunctional CD98/LAT1 complex demonstrates the key role of essential amino acid transport in the control of mTORC1 and tumor growth. Cancer Res. 2016; 76: 4481-4492.
- 83Cormerais Y, Massard PA, Vucetic M, et al. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5). J Biol Chem. 2018; 293: 2877-2887.
- 84Lewerenz J, Hewett SJ, Huang Y, et al. The cystine/glutamate antiporter system xc− in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal. 2013; 18: 522-555.
- 85Nakamura E, Sato M, Yang H, et al. 4F2 (CD98) heavy chain is associated covalently with an amino acid transporter and controls intracellular trafficking and membrane topology of 4F2 heterodimer. J Biol Chem. 1999; 274: 3009-3016.
- 86Koppula P, Zhang Y, Shi J, Li W, Gan B. The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate. J Biol Chem. 2017; 292: 14240-14249.
- 87Daher B, Parks SK, Durivault J, et al. Genetic ablation of the cystine transporter xCT in PDAC cells inhibits mTORC1, growth, survival, and tumor formation via nutrient and oxidative stresses. Cancer Res. 2019; 79: 3877-3890.
- 88Sato M, Kusumi R, Hamashima S, et al. The ferroptosis inducer erastin irreversibly inhibits system xc− and synergizes with cisplatin to increase cisplatin's cytotoxicity in cancer cells. Sci Rep. 2018; 8: 968.
- 89Daher B, Vučetić M, Pouysségur J. Cysteine depletion, a key action to challenge cancer cells to ferroptotic cell death. Front Oncol. 2020; 10: 723.
- 90Lu SC. Regulation of glutathione synthesis. Mol Aspects Med. 2009; 30: 42-59.
- 91Griffith OW. Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic Biol Med. 1999; 27: 922-935.
- 92Shi ZZ, Osei-Frimpong J, Kala G, et al. Glutathione synthesis is essential for mouse development but not for cell growth in culture. Proc Natl Acad Sci U S A. 2000; 97: 5101-5106.
- 93Bansal A, Simon MC. Glutathione metabolism in cancer progression and treatment resistance. J Cell Biol. 2018; 217: 2291-2298.
- 94Dong XQ, Chu LK, Cao X, et al. Glutathione metabolism rewiring protects renal tubule cells against cisplatin-induced apoptosis and ferroptosis. Redox Rep. 2023; 28:2152607.
- 95Hu X, He Y, Han Z, et al. PNO1 inhibits autophagy-mediated ferroptosis by GSH metabolic reprogramming in hepatocellular carcinoma. Cell Death Dis. 2022; 13: 1010.
- 96Xu H, Hu C, Wang Y, et al. Glutathione peroxidase 2 knockdown suppresses gastric cancer progression and metastasis via regulation of kynurenine metabolism. Oncogene. 2023; 42: 1994-2006.
- 97Zhang Z, Wang B, Liu W, Tan B. The regulatory mechanism and research Progress of ferroptosis in gastric cancer. Technol Cancer Res Treat. 2023; 22:15330338231168498.
- 98Forcina GC, Dixon SJ. GPX4 at the crossroads of lipid homeostasis and ferroptosis. Proteomics. 2019; 19:e1800311.
- 99Yant LJ, Ran Q, Rao L, et al. The selenoprotein GPX4 is essential for mouse development and protects from radiation and oxidative damage insults. Free Radic Biol Med. 2003; 34: 496-502.
- 100Ingold I, Berndt C, Schmitt S, et al. Selenium utilization by GPX4 is required to prevent hydroperoxide-induced ferroptosis. Cell. 2018; 172: 409-422.e421.
- 101Cardoso BR, Hare DJ, Bush AI, Roberts BR. Glutathione peroxidase 4: a new player in neurodegeneration? Mol Psychiatry. 2017; 22: 328-335.
- 102Yang WS, SriRamaratnam R, Welsch ME, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014; 156: 317-331.
- 103Zhang X, Sui S, Wang L, et al. Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin. J Cell Physiol. 2020; 235: 3425-3437.
- 104Wu X, Shen S, Qin J, et al. High co-expression of SLC7A11 and GPX4 as a predictor of platinum resistance and poor prognosis in patients with epithelial ovarian cancer. BJOG. 2022; 129(suppl 2): 40-49.
- 105Dai E, Han L, Liu J, et al. Ferroptotic damage promotes pancreatic tumorigenesis through a TMEM173/STING-dependent DNA sensor pathway. Nat Commun. 2020; 11: 6339.
- 106Liu Y, Wan Y, Jiang Y, Zhang L, Cheng W. GPX4: the hub of lipid oxidation, ferroptosis, disease and treatment. Biochim Biophys Acta Rev Cancer. 2023; 1878:188890.
- 107Wang Y, Zheng L, Shang W, et al. Wnt/beta-catenin signaling confers ferroptosis resistance by targeting GPX4 in gastric cancer. Cell Death Differ. 2022; 29: 2190-2202.
- 108Wang R, Hua L, Ma P, et al. HSPA5 repressed ferroptosis to promote colorectal cancer development by maintaining GPX4 stability. Neoplasma. 2022; 69: 1054-1069.
- 109Chen Y, Mi Y, Zhang X, et al. Dihydroartemisinin-induced unfolded protein response feedback attenuates ferroptosis via PERK/ATF4/HSPA5 pathway in glioma cells. J Exp Clin Cancer Res. 2019; 38: 402.
- 110Zhu S, Zhang Q, Sun X, et al. HSPA5 regulates ferroptotic cell death in cancer cells. Cancer Res. 2017; 77: 2064-2077.
- 111Wang Q, Bin C, Xue Q, et al. GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis. Cell Death Dis. 2021; 12: 426.
- 112Shin D, Kim EH, Lee J, Roh JL. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer. Free Radic Biol Med. 2018; 129: 454-462.
- 113Dodson M, Castro-Portuguez R, Zhang DD. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox Biol. 2019; 23:101107.
- 114Bersuker K, Hendricks JM, Li Z, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019; 575: 688-692.
- 115Doll S, Freitas FP, Shah R, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019; 575: 693-698.
- 116Kraft VAN, Bezjian CT, Pfeiffer S, et al. GTP Cyclohydrolase 1/tetrahydrobiopterin counteract ferroptosis through lipid remodeling. ACS Cent Sci. 2020; 6: 41-53.
- 117Mao C, Liu X, Zhang Y, et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature. 2021; 593: 586-590.
- 118Minikes AM, Song Y, Feng Y, Yoon C, Yoon SS, Jiang X. E-cadherin is a biomarker for ferroptosis sensitivity in diffuse gastric cancer. Oncogene. 2023; 42: 848-857.
- 119Decourtye-Espiard L, Guilford P. Hereditary diffuse gastric cancer. Gastroenterology. 2023; 164: 719-735.
- 120Cheng J, Tang YC, Dong Y, Qin RL, Dong ZQ. Doublecortin-like kinase 3 (DCLK3) is associated with bad clinical outcome of patients with gastric cancer and regulates the ferroptosis and mitochondria function in vitro and in vivo. Ir J Med Sci. 2023.
- 121Zhou Q, Liu T, Qian W, et al. HNF4A-BAP31-VDAC1 axis synchronously regulates cell proliferation and ferroptosis in gastric cancer. Cell Death Dis. 2023; 14: 356.
- 122Zang J, Cui M, Xiao L, Zhang J, Jing R. Overexpression of ferroptosis-related genes FSP1 and CISD1 is related to prognosis and tumor immune infiltration in gastric cancer. Clin Transl Oncol. 2023; 25: 2532-2544.
- 123Li Y, Xu X, Wang X, et al. MGST1 expression is associated with poor prognosis, enhancing the Wnt/β-catenin pathway via regulating AKT and inhibiting ferroptosis in gastric cancer. ACS Omega. 2023; 8: 23683-23694.
- 124Xu X, Li Y, Wu Y, et al. Increased ATF2 expression predicts poor prognosis and inhibits sorafenib-induced ferroptosis in gastric cancer. Redox Biol. 2023; 59:102564.
- 125Fu D, Wang C, Yu L, Yu R. Induction of ferroptosis by ATF3 elevation alleviates cisplatin resistance in gastric cancer by restraining Nrf2/Keap1/xCT signaling. Cell Mol Biol Lett. 2021; 26: 26.
- 126Hao S, Yu J, He W, et al. Cysteine dioxygenase 1 mediates erastin-induced ferroptosis in human gastric cancer cells. Neoplasia. 2017; 19: 1022-1032.
- 127Zhang H, Deng T, Liu R, et al. CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol Cancer. 2020; 19: 43.
- 128Wang C, Shi M, Ji J, et al. Stearoyl-CoA desaturase 1 (SCD1) facilitates the growth and anti-ferroptosis of gastric cancer cells and predicts poor prognosis of gastric cancer. Aging. 2020; 12: 15374-15391.
- 129Sun X, Yang S, Feng X, et al. The modification of ferroptosis and abnormal lipometabolism through overexpression and knockdown of potential prognostic biomarker perilipin2 in gastric carcinoma. Gastric Cancer. 2020; 23: 241-259.
- 130Shao Y, Jia H, Li S, et al. Comprehensive analysis of ferroptosis-related markers for the clinical and biological value in gastric cancer. Oxid Med Cell Longev. 2021; 2021:7007933.
- 131Jiang X, Yan Q, Xie L, et al. Construction and validation of a ferroptosis-related prognostic model for gastric cancer. J Oncol. 2021; 2021:6635526.
- 132Liu SJ, Yang YB, Zhou JX, Lin YJ, Pan YL, Pan JH. A novel ferroptosis-related gene risk signature for predicting prognosis and immunotherapy response in gastric cancer. Dis Markers. 2021; 2021:2385406.
- 133Song S, Shu P. Expression of ferroptosis-related gene correlates with immune microenvironment and predicts prognosis in gastric cancer. Sci Rep. 2022; 12: 8785.
- 134Liu G, Ma JY, Hu G, Jin H. Identification and validation of a novel ferroptosis-related gene model for predicting the prognosis of gastric cancer patients. PLoS One. 2021; 16:e0254368.
- 135Zhang Z, Guo M, Li Y, et al. RNA-binding protein ZFP36/TTP protects against ferroptosis by regulating autophagy signaling pathway in hepatic stellate cells. Autophagy. 2020; 16: 1482-1505.
- 136Deng H, Lin Y, Gan F, et al. Prognostic model and immune infiltration of ferroptosis subcluster-related modular genes in gastric cancer. J Oncol. 2022; 2022:5813522.
- 137Wang F, Chen C, Chen WP, Li ZL, Cheng H. Development and validation of a novel ferroptosis-related gene signature for predicting prognosis and the immune microenvironment in gastric cancer. Biomed Res Int. 2021; 2021:6014202.
- 138Murao A, Aziz M, Wang H, Brenner M, Wang P. Release mechanisms of major DAMPs. Apoptosis. 2021; 26: 152-162.
- 139Tang D, Kroemer G, Kang R. Ferroptosis in immunostimulation and immunosuppression. Immunol Rev. 2023.
- 140Neel DV, Basu H, Gunner G, Chiu IM. Catching a killer: mechanisms of programmed cell death and immune activation in amyotrophic lateral sclerosis. Immunol Rev. 2022; 311: 130-150.
- 141Wang W, Green M, Choi JE, et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019; 569: 270-274.
- 142Krovi SH, Kuchroo VK. Activation pathways that drive CD4+ T cells to break tolerance in autoimmune diseases. Immunol Rev. 2022; 307: 161-190.
- 143Zhang ZF, Kurtz RC, Yu GP, et al. Adenocarcinomas of the esophagus and gastric cardia: the role of diet. Nutr Cancer. 1997; 27: 298-309.
- 144Mao SH, Zhu CH, Nie Y, Yu J, Wang L. Levobupivacaine induces ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer. Front Pharmacol. 2021; 12:681338.
- 145Hu C, Zu D, Xu J, et al. Polyphyllin B suppresses gastric tumor growth by modulating iron metabolism and inducing ferroptosis. Int J Biol Sci. 2023; 19: 1063-1079.
- 146Liu Y, Song Z, Liu Y, et al. Identification of ferroptosis as a novel mechanism for antitumor activity of natural product derivative a2 in gastric cancer. Acta Pharm Sin B. 2021; 11: 1513-1525.
- 147Guan D, Zhou W, Wei H, et al. Ferritinophagy-mediated ferroptosis and activation of Keap1/Nrf2/HO-1 pathway were conducive to EMT inhibition of gastric cancer cells in action of 2,2'-Di-pyridineketone hydrazone dithiocarbamate butyric acid ester. Oxid Med Cell Longev. 2022; 2022:3920664.
- 148Li D, Wang Y, Dong C, et al. CST1 inhibits ferroptosis and promotes gastric cancer metastasis by regulating GPX4 protein stability via OTUB1. Oncogene. 2023; 42: 83-98.
- 149Gu R, Xia Y, Li P, et al. Ferroptosis and its role in gastric cancer. Front Cell Dev Biol. 2022; 10:860344.
- 150Huang G, Xiang Z, Wu H, et al. The lncRNA BDNF-AS/WDR5/FBXW7 axis mediates ferroptosis in gastric cancer peritoneal metastasis by regulating VDAC3 ubiquitination. Int J Biol Sci. 2022; 18: 1415-1433.
- 151Lin Z, Song J, Gao Y, et al. Hypoxia-induced HIF-1α/lncRNA-PMAN inhibits ferroptosis by promoting the cytoplasmic translocation of ELAVL1 in peritoneal dissemination from gastric cancer. Redox Biol. 2022; 52:102312.
- 152Gao Z, Deng G, Li Y, et al. Actinidia chinensis planch prevents proliferation and migration of gastric cancer associated with apoptosis, ferroptosis activation and mesenchymal phenotype suppression. Biomed Pharmacother. 2020; 126:110092.
- 153Yu J, Zhong B, Zhao L, et al. Fighting drug-resistant lung cancer by induction of NAD(P)H:quinone oxidoreductase 1 (NQO1)-mediated ferroptosis. Drug Resist Updat. 2023; 70:100977.
- 154Sun X, Niu X, Chen R, et al. Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology. 2016; 64: 488-500.
- 155Feng S, Li Y, Huang H, et al. Isoorientin reverses lung cancer drug resistance by promoting ferroptosis via the SIRT6/Nrf2/GPX4 signaling pathway. Eur J Pharmacol. 2023; 954:175853.
- 156Wei L, Sun J, Zhang N, et al. Noncoding RNAs in gastric cancer: implications for drug resistance. Mol Cancer. 2020; 19: 62.
- 157Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014; 15: 49-63.
- 158Dutta R, Tiu B, Kaul A, Mitton B, Sakamoto KM. CREB increases chemotherapy resistance through regulation of the DNA damage repair pathway in AML cells. Blood. 2015; 126: 1390.
- 159Jiang Y, Cheng J, Yang C, et al. An ultrasensitive fluorogenic probe for revealing the role of glutathione in chemotherapy resistance. Chem Sci. 2017; 8: 8012-8018.
- 160Cai S, Fu S, Zhang W, Yuan X, Cheng Y, Fang J. SIRT6 silencing overcomes resistance to sorafenib by promoting ferroptosis in gastric cancer. Biochem Biophys Res Commun. 2021; 577: 158-164.
- 161Yuan J, Khan SU, Yan J, Lu J, Yang C, Tong Q. Baicalin enhances the efficacy of 5-fluorouracil in gastric cancer by promoting ROS-mediated ferroptosis. Biomed Pharmacother. 2023; 164:114986.
- 162Desbois M, Wang Y. Cancer-associated fibroblasts: key players in shaping the tumor immune microenvironment. Immunol Rev. 2021; 302: 241-258.
- 163Qu X, Liu B, Wang L, et al. Loss of cancer-associated fibroblast-derived exosomal DACT3-AS1 promotes malignant transformation and ferroptosis-mediated oxaliplatin resistance in gastric cancer. Drug Resist Updat. 2023; 68:100936.
- 164Geng D, Wu H. Abrogation of ARF6 in promoting erastin-induced ferroptosis and mitigating capecitabine resistance in gastric cancer cells. J Gastrointest Oncol. 2022; 13: 958-967.
- 165Du Y, Guo Z. Recent progress in ferroptosis: inducers and inhibitors. Cell Death Discov. 2022; 8: 501.
- 166Song Q, Peng S, Sun Z, Heng X, Zhu X. Temozolomide drives ferroptosis via a DMT1-dependent pathway in glioblastoma cells. Yonsei Med J. 2021; 62: 843-849.
- 167Hassannia B, Wiernicki B, Ingold I, et al. Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma. J Clin Invest. 2018; 128: 3341-3355.
- 168NaveenKumar SK, Hemshekhar M, Kemparaju K, et al. Hemin-induced platelet activation and ferroptosis is mediated through ROS-driven proteasomal activity and inflammasome activation: protection by melatonin. Biochim Biophys Acta Mol Basis Dis. 2019; 1865: 2303-2316.
- 169Chen GQ, Benthani FA, Wu J, Liang D, Bian ZX, Jiang X. Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis. Cell Death Differ. 2020; 27: 242-254.
- 170Li ZJ, Dai HQ, Huang XW, et al. Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma. Acta Pharmacol Sin. 2021; 42: 301-310.
- 171Gaschler MM, Andia AA, Liu H, et al. FINO(2) initiates ferroptosis through GPX4 inactivation and iron oxidation. Nat Chem Biol. 2018; 14: 507-515.
- 172Abrams RP, Carroll WL, Woerpel KA. Five-membered ring peroxide selectively initiates ferroptosis in cancer cells. ACS Chem Biol. 2016; 11: 1305-1312.
- 173Wenz C, Faust D, Linz B, et al. T-BuOOH induces ferroptosis in human and murine cell lines. Arch Toxicol. 2018; 92: 759-775.
- 174Dolma S, Lessnick SL, Hahn WC, Stockwell BR. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell. 2003; 3: 285-296.
- 175Seibt TM, Proneth B, Conrad M. Role of GPX4 in ferroptosis and its pharmacological implication. Free Radic Biol Med. 2019; 133: 144-152.
- 176Dixon SJ, Patel DN, Welsch M, et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. eLife. 2014; 3:e02523.
- 177Larraufie MH, Yang WS, Jiang E, Thomas AG, Slusher BS, Stockwell BR. Incorporation of metabolically stable ketones into a small molecule probe to increase potency and water solubility. Bioorg Med Chem Lett. 2015; 25: 4787-4792.
- 178Zhang Y, Tan H, Daniels JD, et al. Imidazole ketone Erastin induces ferroptosis and slows tumor growth in a mouse lymphoma model. Cell Chem Biol. 2019; 26: 623-633.e629.
- 179Nashed MG, Ungard RG, Young K, et al. Behavioural effects of using sulfasalazine to inhibit glutamate released by cancer cells: a novel target for cancer-induced depression. Sci Rep. 2017; 7:41382.
- 180Hu K, Li K, Lv J, et al. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma. J Clin Invest. 2020; 130: 1752-1766.
- 181Yang WS, Stockwell BR. Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 2016; 26: 165-176.
- 182Weïwer M, Bittker JA, Lewis TA, et al. Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorg Med Chem Lett. 2012; 22: 1822-1826.
- 183Eaton JK, Furst L, Ruberto RA, et al. Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles. Nat Chem Biol. 2020; 16: 497-506.
- 184Viswanathan VS, Ryan MJ, Dhruv HD, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017; 547: 453-457.
- 185Woo JH, Shimoni Y, Yang WS, et al. Elucidating compound mechanism of action by network perturbation analysis. Cell. 2015; 162: 441-451.
- 186Liu S, Zhang HL, Li J, et al. Tubastatin a potently inhibits GPX4 activity to potentiate cancer radiotherapy through boosting ferroptosis. Redox Biol. 2023; 62:102677.
- 187Shimada K, Skouta R, Kaplan A, et al. Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. Nat Chem Biol. 2016; 12: 497-503.
- 188Yang L, Chen X, Yang Q, et al. Broad spectrum deubiquitinase inhibition induces both apoptosis and ferroptosis in cancer cells. Front Oncol. 2020; 10: 949.
- 189Warner GJ, Berry MJ, Moustafa ME, Carlson BA, Hatfield DL, Faust JR. Inhibition of selenoprotein synthesis by selenocysteine tRNA[ser]sec lacking isopentenyladenosine. J Biol Chem. 2000; 275: 28110-28119.
- 190Basit F, van Oppen LM, Schöckel L, et al. Mitochondrial complex I inhibition triggers a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis in melanoma cells. Cell Death Dis. 2017; 8:e2716.
- 191Koppula P, Zhang Y, Zhuang L, Gan B. Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun. 2018; 38: 12.
- 192Li FJ, Long HZ, Zhou ZW, Luo HY, Xu SG, Gao LC. System Xc−/GSH/GPX4 axis: an important antioxidant system for the ferroptosis in drug-resistant solid tumor therapy. Front Pharmacol. 2022; 13:910292.
- 193Liu MR, Zhu WT, Pei DS. System Xc−: a key regulatory target of ferroptosis in cancer. Invest New Drugs. 2021; 39: 1123-1131.
- 194Paul BD, Sbodio JI, Snyder SH. Cysteine metabolism in neuronal redox homeostasis. Trends Pharmacol Sci. 2018; 39: 513-524.
- 195Cao JY, Dixon SJ. Mechanisms of ferroptosis. Cell Mol Life Sci. 2016; 73: 2195-2209.
- 196Liang C, Zhang X, Yang M, Dong X. Recent progress in ferroptosis inducers for cancer therapy. Adv Mater. 2019; 31:e1904197.
- 197Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell. 2017; 170: 17-33.
- 198Yao X, Zhang Y, Hao J, et al. Deferoxamine promotes recovery of traumatic spinal cord injury by inhibiting ferroptosis. Neural Regen Res. 2019; 14: 532-541.
- 199Rayatpour A, Foolad F, Heibatollahi M, Khajeh K, Javan M. Ferroptosis inhibition by deferiprone, attenuates myelin damage and promotes neuroprotection in demyelinated optic nerve. Sci Rep. 2022; 12:19630.
- 200Miotto G, Rossetto M, Di Paolo ML, et al. Insight into the mechanism of ferroptosis inhibition by ferrostatin-1. Redox Biol. 2020; 28:101328.
- 201Friedmann Angeli JP, Schneider M, Proneth B, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014; 16: 1180-1191.
- 202Fan BY, Pang YL, Li WX, et al. Liproxstatin-1 is an effective inhibitor of oligodendrocyte ferroptosis induced by inhibition of glutathione peroxidase 4. Neural Regen Res. 2021; 16: 561-566.
- 203Saito Y. Diverse cytoprotective actions of vitamin E isoforms- role as peroxyl radical scavengers and complementary functions with selenoproteins. Free Radic Biol Med. 2021; 175: 121-129.
- 204Conrad M, Pratt DA. The chemical basis of ferroptosis. Nat Chem Biol. 2019; 15: 1137-1147.
- 205Mishima E, Ito J, Wu Z, et al. A non-canonical vitamin K cycle is a potent ferroptosis suppressor. Nature. 2022; 608: 778-783.
- 206Vervoort LM, Ronden JE, Thijssen HH. The potent antioxidant activity of the vitamin K cycle in microsomal lipid peroxidation. Biochem Pharmacol. 1997; 54: 871-876.
- 207Hinman A, Holst CR, Latham JC, et al. Vitamin E hydroquinone is an endogenous regulator of ferroptosis via redox control of 15-lipoxygenase. PLoS One. 2018; 13:e0201369.
- 208Zhao J, Wu Y, Liang S, Piao X. Activation of SSAT1/ALOX15 Axis aggravates cerebral ischemia/reperfusion injury via triggering neuronal ferroptosis. Neuroscience. 2022; 485: 78-90.
- 209Liu Y, Wang W, Li Y, Xiao Y, Cheng J, Jia J. The 5-lipoxygenase inhibitor zileuton confers neuroprotection against glutamate oxidative damage by inhibiting ferroptosis. Biol Pharm Bull. 2015; 38: 1234-1239.
- 210Lee JJ, Chang-Chien GP, Lin S, et al. 5-lipoxygenase inhibition protects retinal pigment epithelium from sodium iodate-induced ferroptosis and prevents retinal degeneration. Oxid Med Cell Longev. 2022; 2022:1792894.
- 211Jung KH, Kim SE, Go HG, et al. Synergistic Renoprotective effect of melatonin and zileuton by inhibition of ferroptosis via the AKT/mTOR/NRF2 signaling in kidney injury and fibrosis. Biomol Ther. 2023.
- 212Wei S, Qiu T, Wang N, et al. Ferroptosis mediated by the interaction between Mfn2 and IREα promotes arsenic-induced nonalcoholic steatohepatitis. Environ Res. 2020; 188:109824.
- 213Wang Y, Bi R, Quan F, et al. Ferroptosis involves in renal tubular cell death in diabetic nephropathy. Eur J Pharmacol. 2020; 888:173574.
- 214Zhang M, Qin L, Qin Y, et al. 287-LB: thiazolidinedione ameliorates lipotoxicity-induced pancreatic β-cell ferroptosis partly via ACSL4. Diabetes. 2023; 72: 287-LB.
- 215Ji Q, Fu S, Zuo H, et al. ACSL4 is essential for radiation-induced intestinal injury by initiating ferroptosis. Cell Death Discov. 2022; 8: 332.
- 216Khanna S, Roy S, Ryu H, et al. Molecular basis of vitamin E action: tocotrienol modulates 12-lipoxygenase, a key mediator of glutamate-induced neurodegeneration. J Biol Chem. 2003; 278: 43508-43515.
Citing Literature
